ArticleBMC medicine2023
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank.
Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- Long-Term Multisystem Comorbidity Patterns in Acute Pancreatitis: Insights From Observational and Genetic Analysis.United European gastroenterology journal · 2026Observational
- Metabolic dysfunction associated steatotic liver disease, cardiometabolic multimorbidity and mortality: evidence from the UK biobank.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- DiNetxify-a python package for three‑dimensional disease network analysis based on electronic health record data.European journal of epidemiology · 2026Article
- Association between atherosclerosis-related indicators and fatty liver: a population-based observational study.European journal of medical research · 2025Observational
- Investigating multimorbidity trajectories in people living with MASLD diagnosis: A trajectory analysis using the UK Biobank.Diabetes, obesity & metabolism · 2025Article
- Survival machine learning models for predicting all-cause and case-specific mortality risk in metabolic dysfunction-associated fatty liver disease patients.Scientific reports · 2025Article
- Disease clusters and death trajectories in individuals with frailty: a prospective cohort study from the UK Biobank.BMC public health · 2025Article
- Disease trajectory and mortality among sepsis patients: a prospective cohort study.BMC infectious diseases · 2025Article
- Sex-Stratified Prediction Models for 5-Year Nonalcoholic Fatty Liver Disease Risk in Thyroid Cancer Patients: A Nationwide Cohort Study.Biomedicines · 2025Article
- Exploring population and sex-specific disease trajectories for multimorbidities among individuals with overweight or obesity: A retrospective cohort study in UK biobank.Diabetes, obesity & metabolism · 2025Article
- Circulating ORM2 as a Biomarker of Metabolic Dysfunction: Evidence from the KADEM Study in Kuwaiti Adults.International journal of molecular sciences · 2025Article
- [Predictive value of a Chinese visceral adiposity index for metabolic associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Machine learning survival models for Non-alcoholic fatty liver disease based on a health checkup cohort.BMC gastroenterology · 2025Article
- Metabolic dysfunction associated steatotic liver disease is associated with an increased risk of multiple respiratory system diseases.Scientific reports · 2025Article
- Increased risk of multisystem comorbidities and disease trajectories following hyperthyroidism: evidence from the 0.5 million UK Biobank population.Endocrine connections · 2025Article
- Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- The association of chronic pain, painkiller use, and potential mediators with liver fat content.Scientific reports · 2025Article
- Predicting colorectal adenomatous polyps in patients with chronic liver disease: A novel nomogram.World journal of gastroenterology · 2025Article
- Association of sugary beverages consumption with liver fat content and fibro-inflammation: a large cohort study.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is a newly defined condition encompassing hepatic steatosis and metabolic dysfunction. However, the relationship between MAFLD and multi-system diseases remains unclear, and the time-dependent sequence of these diseases requires further clarification.
methodsAfter propensity score matching, 163,303 MAFLD subjects and 163,303 matched subjects were included in the community-based UK Biobank study. The International Classification of Diseases, Tenth Revision (ICD-10), was used to reclassify medical conditions into 490 and 16 specific causes of death. We conducted a disease trajectory analysis to map the key pathways linking MAFLD to various health conditions, providing an overview of their interconnections.
resultsParticipants aged 59 (51-64) years, predominantly males (62.5%), were included in the study. During the 12.9-year follow-up period, MAFLD participants were found to have a higher risk of 113 medical conditions and eight causes of death, determined through phenome-wide association analysis using Cox regression models. Temporal disease trajectories of MAFLD were established using disease pairing, revealing intermediary diseases such as asthma, diabetes, hypertension, hypothyroid conditions, tobacco abuse, diverticulosis, chronic ischemic heart disease, obesity, benign tumors, and inflammatory arthritis. These trajectories primarily resulted in acute myocardial infarction, disorders of fluid, electrolyte, and acid-base balance, infectious gastroenteritis and colitis, and functional intestinal disorders. Regarding death trajectories of MAFLD, malignant neoplasms, cardiovascular diseases, and respiratory system deaths were the main causes, and organ failure, infective disease, and internal environment disorder were the primary end-stage conditions. Disease trajectory analysis based on the level of genetic susceptibility to MAFLD yielded consistent results.
conclusionsIndividuals with MAFLD have a risk of a number of different medical conditions and causes of death. Notably, these diseases and potential causes of death constitute many pathways that may be promising targets for preventing general health decline in patients with MAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.